Science · The platform
Pharmaceutical-grade CBD, finally.
Liquid Structure™ is a patented delivery technology invented at Hebrew University of Jerusalem and exclusively licensed to Ananda. Tailored to the molecular geometry of CBD, it forms self-emulsifying nano-domains that achieve superior absorption, low variability, and no food effect — the bioavailability wall, dissolved.
The platform
The bioavailability wall.
Cannabidiol is highly lipophilic, with poor and variable oral absorption, a strong food-fat dependence, and unpredictable response. These properties have prevented CBD from being studied as a real drug — until now.
The problem · Standard CBD formulations are unfit for clinical use
Variability
4–10× inter-subject variability in plasma exposure
Food effect
4–5× increase in absorption with high-fat meal
Onset
Slow, unpredictable Tmax of 3–5 hours
Dose-response
Non-linear, often saturating at supra-clinical doses
Nantheia™ on Liquid Structure™
Self-assembling nano-domains.
A thermodynamically stable system of inverse nano-domains, 10–200 nm, monodispersed in a high-water environment. CBD partitions into the lipophilic core; the surfactant shell self-emulsifies on contact with GI fluid; absorption proceeds through lymphatic and portal pathways without dependence on dietary fat.
- CBD core (lipophilic API)
- Solubilized in oil-phase nano-domain core
- Surfactant shell
- Pharma-grade emulsifier · GRAS materials
- Co-solvent matrix
- Drives self-assembly on hydration
- Domain edge
- 10–200 nm · monodispersed · cryo-TEM verified
- Aqueous phase
- High-water — physiologic compatibility
Compositions · ATL5 · A1002 · ATL3
Three Nantheia™ compositions tuned for indication-specific dose, onset profile, and dosing schedule. ATL5 is the lead asset across PTSD, OUD, smoking, and AD; A1002 is optimized for acute SAD challenge.
PK performance
Higher Cmax. Shorter Tmax. No food effect.
Phase I PK study in 24 healthy volunteers, single oral dose, fed and fasted arms, crossover design. Liquid Structure™ Nantheia™ ATL5 demonstrated superior performance versus FDA-approved Epidiolex® across all measured parameters.
Fig. 04 · Plasma exposure curves
Nantheia™ ATL5 vs Epidiolex® — single oral dose, fasted
Source: Phase I PK · 24-subject crossover · single dose · fed/fasted · data on file. Results illustrative; precise values under CDA.
Mechanism of action
Multifactorial — by design.
CBD acts at multiple receptors simultaneously, a property that lets a single molecule address the symptom heterogeneity of PTSD and related neuropsychiatric disease.
Modulates fear-extinction circuitry · indirect agonism
Anxiolytic · antidepressant signaling
Pain · inflammation · thermal regulation
Inhibits anandamide breakdown · indirect endocannabinoid tone
Manufacturing
cGMP from API to softgel.
A pharma-grade supply chain — from pharmaceutical-grade CBD API through cGMP softgel encapsulation at a tier-1 contract manufacturer. Process is scalable to commercial volumes with the existing supply network.
- 01
Pharma-grade CBD API
GMP-certified suppliers · USP/EP grade
- 02
Liquid Structure™ assembly
Proprietary process · pharma CMO
- 03
Softgel encapsulation
cGMP · scalable to 10M+ units/yr
- 04
Stability / release
4+ years ambient · ICH-aligned
- 05
Distribution
Cold-chain not required · pharmacy direct
Patents & IP
Composition of matter, granted.
The Liquid Structure™ platform is protected by composition-of-matter patents in 30+ jurisdictions, exclusively licensed from Yissum (Hebrew University) to Ananda. Additional Ananda-owned patents extend protection through indication-specific compositions and methods of treatment.
| Family | Type | Status | Coverage | Expiry |
|---|---|---|---|---|
| Liquid Structure™ (platform) | Composition of matter | GRANTED | 30+ jurisdictions · US, EU, JP, CN | Through 2034+ |
| Nantheia™ ATL5 (lead) | Composition · indication | GRANTED / PENDING | PTSD · OUD · smoking · AD | Through 2038+ |
| Nantheia™ A1002 | Composition · indication | PENDING | SAD · acute anxiolytic | Through 2040+ |
| Manufacturing process | Method of manufacture | GRANTED | Trade secret + patent | Indefinite (TS) |
| Methods of treatment | Use claims | GRANTED / PENDING | Six neuropsychiatric indications | Through 2038+ |
Detailed patent landscape and family map available under CDA.